Comparative efficacy of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of vascular calcification in patients with haemodialysis: a systematic review and network meta-analysis
Up to now, there is no unequivocal intervention to mitigate vascular calcification (VC) in patients with hemodialysis. This network meta-analysis aimed to systematically evaluate the clinical efficacy of sodiu... (Source: BMC Nephrology)
Source: BMC Nephrology - January 22, 2024 Category: Urology & Nephrology Authors: Lei He, Yuzhe Li, Jingjing Jin, Meijuan Cheng, Yaling Bai and Jinsheng Xu Tags: Research Source Type: research
The authors reply
In podocyte-specific calcium-sensing receptor knockout mice, we recently demonstrated a role of calcium-sensing receptor signaling in control of glomerular disease and the therapeutic potential of calcimimetics.1,2 Off-label therapy with cinacalcet together with oral calcium in 4 children with nephrotic syndrome was well tolerated, reduced proteinuria by up to 96%, and resolved edema. Early viral infection –related relapses, however, suggested that the effect of calcium-sensing receptor stimulation was counteracted by additional immunologic triggers. (Source: Kidney International)
Source: Kidney International - January 18, 2024 Category: Urology & Nephrology Authors: Anne K. M ühlig, Claus-Peter Schmitt, Jun Oh Tags: Letter to the Editor Source Type: research
Cinacalcet in focal segmental glomerular sclerosis: a case report
We read with interest the article by M ühlig et al.,1 recently published in Kidney International. Drug-resistant focal segmental glomerular sclerosis is an open issue, and these patients often rapidly progress to end-stage renal disease.2 In such a setting, any potential new drug is welcome.3 The authors demonstrated that calcium-sensi ng receptor knockout mice manifest up to 3 times proteinuria with respect to wild-type mice when treated with adriamycin. Moreover, the administration of cinacalcet to wild-type mice significantly reduced proteinuria in this model. (Source: Kidney International)
Source: Kidney International - January 18, 2024 Category: Urology & Nephrology Authors: Corrado Murtas, Roberta Guastini, Emanuela Cristi, Teresa Valentina Ranalli, Sandro Feriozzi Tags: Letter to the Editor Source Type: research
Chronic Cinacalcet improves skin flap survival in rats: the suggested role of the nitric oxide pathway
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan 6. doi: 10.1007/s00210-023-02922-7. Online ahead of print.ABSTRACTCinacalcet is a calcimimetic medicine that has been used to treat secondary hyperparathyroidism and parathyroid cancer. Various studies have proposed the positive role of calcium and its receptor in skin wound healing. Furthermore, Cinacalcet interacts with other skin repair-related mechanisms, including inflammation and nitric oxide pathways. The present study evaluated the effect of Cinacalcet on the random-pattern skin flap survival. Eighty-four Wistar male rats were used. Multiple doses of Cinacalcet (30, 3, ...
Source: Cancer Control - January 6, 2024 Category: Cancer & Oncology Authors: Mostafa Akbariani Farahnaz Bidari Zerehpoosh Zohreh Shahabi Amir Shadboorestan Zahra Hami Ehsan Nasiroleslami Sevda Shayesteh Mohsen Chamanara Ahmad Reza Dehpour Source Type: research
< em > GCM2 < /em > p.Tyr394Ser variant in Ashkenazi Israeli patients with suspected familial isolated hyperparathyroidism
CONCLUSION: In contrast to previous observations, the GCM2 p.Tyr394Ser variant-associated phenotype may be mild in AJ with FIHP, sometimes mimicking FHH. Because surgery may be curative, surgeons should be aware of the possibility of multiple gland diseases in these patients. The clinical spectrum and clinical utility of screening for this variant warrant further investigation.PMID:38130397 | PMC:PMC10733520 | DOI:10.3389/fendo.2023.1254156 (Source: Atherosclerosis)
Source: Atherosclerosis - December 22, 2023 Category: Cardiology Authors: Auryan Szalat Shoshana Shpitzen Rena Pollack Haggi Mazeh Ronen Durst Vardiella Meiner Source Type: research
GCM2 p.Tyr394Ser variant in Ashkenazi Israeli patients with suspected familial isolated hyperparathyroidism
ConclusionIn contrast to previous observations, the GCM2 p.Tyr394Ser variant-associated phenotype may be mild in AJ with FIHP, sometimes mimicking FHH. Because surgery may be curative, surgeons should be aware of the possibility of multiple gland diseases in these patients. The clinical spectrum and clinical utility of screening for this variant warrant further investigation. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 7, 2023 Category: Endocrinology Source Type: research
Parathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism
CONCLUSION: PTX still seems to be the best treatment choice for SHPT, especially in patients with prolonged diseases in unresourceful scenarios.PMID:38039492 | DOI:10.1590/2175-8239-JBN-2023-0024en (Source: Jornal Brasileiro de Nefrologia)
Source: Jornal Brasileiro de Nefrologia - December 1, 2023 Category: Urology & Nephrology Authors: Luiz Guilherme Fernandes Ramos Daniela Del Pilar Via Reque Cortes Luciene Machado Dos Reis Fabio Luiz de Menezes Montenegro S érgio Samir Arap Mar ília D'Elboux Guimarães Brescia Melani Ribeiro Cust ódio Vanda Jorgetti Rosilene Motta Elias Rosa Maria Source Type: research
Calcitonin/Cinacalcet/Sodium-chloride
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival
CONCLUSIONS: This study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.PMID:38006197 | DOI:10.1093/oncolo/oyad314 (Source: The Oncologist)
Source: The Oncologist - November 25, 2023 Category: Cancer & Oncology Authors: Rongzhi Wang Rhiannon D Reed Griffin Price Peter Abraham Marshall Lewis Jessica Liu McMullin Paul MacLennan Cozette Killian Jayme E Locke Song Ong Vineeta Kumar Andrea Gillis Brenessa Lindeman Herbert Chen Jessica Fazendin Source Type: research
Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival
CONCLUSIONS: This study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.PMID:38006197 | DOI:10.1093/oncolo/oyad314 (Source: The Oncologist)
Source: The Oncologist - November 25, 2023 Category: Cancer & Oncology Authors: Rongzhi Wang Rhiannon D Reed Griffin Price Peter Abraham Marshall Lewis Jessica Liu McMullin Paul MacLennan Cozette Killian Jayme E Locke Song Ong Vineeta Kumar Andrea Gillis Brenessa Lindeman Herbert Chen Jessica Fazendin Source Type: research
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Transl Res. 2023 Oct 30:S1931-5244(23)00177-9. doi: 10.1016/j.trsl.2023.10.005. Online ahead of print.ABSTRACTADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl- and fluid secretion in various epithelial cell...
Source: Translational Research : the journal of laboratory and clinical medicine - November 22, 2023 Category: Laboratory Medicine Authors: Pattareeya Yottasan Tifany Chu Parth D Chhetri Onur Cil Source Type: research
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Transl Res. 2023 Oct 30:S1931-5244(23)00177-9. doi: 10.1016/j.trsl.2023.10.005. Online ahead of print.ABSTRACTADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl- and fluid secretion in various epithelial cell...
Source: Cell Research - November 22, 2023 Category: Cytology Authors: Pattareeya Yottasan Tifany Chu Parth D Chhetri Onur Cil Source Type: research
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Transl Res. 2023 Oct 30:S1931-5244(23)00177-9. doi: 10.1016/j.trsl.2023.10.005. Online ahead of print.ABSTRACTADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl- and fluid secretion in various epithelial cell...
Source: Translational Research : the journal of laboratory and clinical medicine - November 22, 2023 Category: Laboratory Medicine Authors: Pattareeya Yottasan Tifany Chu Parth D Chhetri Onur Cil Source Type: research
